跳到主要內容

Smith Stan 的 Form 4/A 修正申報

修正

MAIA Biotechnology, Inc.MAIA,2025/3/5 申報

申報編號
0001127602-25-008322
申報時間
2025/3/5
交易日
2025/2/24
申報延遲
9 天
10b5-1 計畫
沒有勾選
原始申報日
2025/2/25

這份申報列了 1 筆非衍生性交易、1 筆衍生性交易。公開市場買進合計 $7.50 萬。交易後 9 天申報。

這份修正申報取代了 0001127602-25-006574(2025/2/25 申報)。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Smith StanCIK 0001913199董事

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2025/2/24Common StockP買進取得+50,000$1.50+$75,0001,180,060間接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2025/2/24Common StockP買進取得+50,000$1.87+$93,50050,000間接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025.

F2

These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3

This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 3 to "February 24, 2025".

F4

These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the inital issuance date.

F5

These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

看 SEC EDGAR 上的完整原文 (在新分頁開啟)